CLRB News and Press, Cellectar Biosciences Inc. From 05/07/20

Cellectar Biosciences (NASDAQ: CLRB ): Q1 GAAP EPS of -$0.42 misses by $0.07 . More news on: Cellectar Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

FLORHAM PARK, N.J., May 07, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the three ...

Cellectar Biosciences (NASDAQ: CLRB ): FY GAAP EPS of -$1.84 beats by $0.05 . More news on: Cellectar Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

FLORHAM PARK, N.J., March 09, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the year...

Tivity Health (NASDAQ: TVTY )  -39%  on Q4 earnings . More news on: Tivity Health, Inc., Six Flags Entertainment Corporation, BioXcel Therapeutics, Inc., Stocks on the move, Read more ...

Gainers: Myomo (NYSEMKT: MYO ) +48% . More news on: Myomo, Inc., Enphase Energy, Inc., Altisource Asset Management Corporation, Stocks on the move, , Read more ...

Thinly traded nano cap Cellectar Biosciences (NASDAQ: CLRB ) slumps  23%  premarket on increased volume in reaction to results from a Phase 2 clinical trial, CLOVER-1 , evaluating lead candidater CLR 131 in patients with relapsed/refractory B-cell lymphomas. More news on: Cell...

42.8% ORR in multiple myeloma at the 75mCi total body dose 42.0% ORR and 11% CRR in all non-Hodgkin’s lymphoma (NHL) patients 100% ORR seen in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia (LPL/WM) patients 76.7% of the multiple myeloma ...

Are These The Best Stocks To Trade Before The End Of February 2020? It goes without saying that investing in penny stocks comes with a certain level of risk. But at the same time, these cheap stocks can often generate substantial returns in a short period of time. Over the years, plenty of...

The following slide deck was published by Cellectar Biosciences, Inc. in conjunction with this Read more ...